Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Alicia J, Allred"'
Autor:
Julie R. Brahmer, MD, Melissa L. Johnson, MD, Manuel Cobo, MD, PhD, Santiago Viteri, MD, Juan Coves Sarto, MD, Ammar Sukari, MD, Mark M. Awad, MD, PhD, Ravi Salgia, MD, PhD, Vali A. Papadimitrakopoulou, MD, Arun Rajan, MD, Nibedita Bandyopadhyay, PhD, Alicia J. Allred, PhD, Mark Wade, MA, Gary E. Mason, MD, Enrique Zudaire, PhD, Roland E. Knoblauch, MD, PhD, Nicole Stone, PhD, Matthew V. Lorenzi, PhD, Raffit Hassan, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100103- (2021)
Introduction: JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted Listeria monocytogenes–based immunotherapy expressing human mesothelin. JNJ-757 was evaluated in patients with advanced NSCLC as monotherapy (phase 1) and in combination wit
Externí odkaz:
https://doaj.org/article/bbb4d20374c844f282e02141b37f3640
Autor:
Sarah P. Blagden, Johann S. de Bono, Richard Wilson, Mohammed M. Dar, Thomas A. Lampkin, Sharon C. Murray, Deborah A. Smith, Alicia J. Allred, Yan Y. Degenhardt, Hanine Medani, Jorge Barriuso, Anne B. Taegtmeyer, Timothy A. Yap, Andre T. Brunetto, Rohini Sharma, Douglas Barker, David Olmos
Supplementary Methods; Supplementary Table S1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa656e44c9db5425b374f6954cb9ce23
https://doi.org/10.1158/1078-0432.22441227
https://doi.org/10.1158/1078-0432.22441227
Autor:
Sarah P. Blagden, Johann S. de Bono, Richard Wilson, Mohammed M. Dar, Thomas A. Lampkin, Sharon C. Murray, Deborah A. Smith, Alicia J. Allred, Yan Y. Degenhardt, Hanine Medani, Jorge Barriuso, Anne B. Taegtmeyer, Timothy A. Yap, Andre T. Brunetto, Rohini Sharma, Douglas Barker, David Olmos
Purpose: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1). A phase I study of two schedules of intravenous GSK461364 was conducted.Experimental Design: GSK461364 was administered in escalating doses to patients with solid malign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff23bf4b14372b8aa854f554ab505b1
https://doi.org/10.1158/1078-0432.c.6518349
https://doi.org/10.1158/1078-0432.c.6518349
Autor:
Syed Rizvi, Frank Fan, David Avigan, Jenna D. Goldberg, Farah Hossain, Muhammad Akram, Jeffrey R. Infante, Andrzej Jakubowiak, Tzu-Min Yeh, Deepu Madduri, Adam D. Cohen, Alicia J. Allred, Jesus G. Berdeja, Enrique Zudaire, Sen Hong Zhuang, Parameswaran Hari, Jordan M. Schecter, Nikhil C. Munshi, Marlene J. Carrasco, Abhinav Deol, William Deraedt, Saad Z. Usmani, Thomas Martin, Mounzer Agha, Alexander M. Lesokhin, Dong Geng, Indrajeet Singh, Carolyn C. Jackson, Myo Htut, Elizabeth O'Donnell, Yunsi Olyslager, A. Keith Stewart, Arnob Banerjee, Sundar Jagannath, Xiaoling Wu, Yi Lin
Publikováno v:
Blood. 136:22-25
Background: Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells) is a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity. In the phase
Autor:
Alicia J. Allred, Jesus G. Berdeja, Lynda C. Doward, Jordan M. Schecter, Parameswaran Hari, Katharine S. Gries, Yunsi Olyslager, Sundar Jagannath, Carolyn C. Jackson, John Fastenau, Rebecca Crawford, Ross Morrison, Myo Htut, Saad Z. Usmani, William Deraedt, Farah Hossain, Muhammad Akram, Deepu Madduri, Marlene Carrasco-Alfonso, Jenna D. Goldberg, Arnob Banerjee, Andrzej Jakubowiak, Adam D. Cohen
Publikováno v:
Blood. 136:13-15
Background: Patients (pts) with multiple myeloma (MM) experience health-related quality of life (HRQoL) decrement due to symptoms such as fatigue, pain, and insomnia. Pt perspectives of their disease and treatment expectations can help inform clinica
Autor:
Sen Hong Zhuang, Elizabeth O'Donnell, Syed Rizvi, Saad Z. Usmani, Myo Htut, Jenna D. Goldberg, Jesus G. Berdeja, Xiaoling Wu, Abhinav Deol, David Avigan, Andrzej Jakubowiak, Jordan M. Schecter, Dong Geng, Muhammad Akram, Parameswaran Hari, William Deraedt, Indrajeet Singh, Farah Hossain, Deepu Madduri, Sundar Jagannath, Tzu-Min Yeh, Mounzer Agha, Jeffrey R. Infante, Carolyn C. Jackson, Nikhil C. Munshi, Alicia J. Allred, Frank Fan, Marlene J Carrasco-Alfonso, A. Keith Stewart, Arnob Banerjee, Yi Lin, Enrique Zudaire, Yunsi Olyslager, Alexander M. Lesokhin, Adam D. Cohen, Thomas Martin
Publikováno v:
Lancet (London, England). 398(10297)
Summary Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients wi
Autor:
Adam B. Cohen, Yunsi Olyslager, Carolyn C. Jackson, Mounzer Agha, Saad Z. Usmani, Jesus G. Berdeja, Muhammad Akram, Arnob Banerjee, Andrzej Jakubowiak, Alicia J. Allred, Thomas Martin, William Deraedt, Parameswaran Hari, Deepu Madduri, Yi Lin, Lida Bubuteishvili Pacaud, Tzu-Min Yeh, Sundar Jagannath, Xiaoling Wu, Enrique Zudaire
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S15-S16
Background Ciltacabtagene autoleucel (cilta-cel) is a CAR-T cell therapy with two B-cell maturation antigen–targeting single-domain antibodies. The phase 1b/2 CARTITUDE-1 study is evaluating cilta-cel in patients (pts) with RRMM. Here we report upd
Autor:
Mounzer Agha, Saad Z. Usmani, Alicia J. Allred, Xiaoling Wu, Enrique Zudaire, Thomas Martin, Jesus G. Berdeja, Arnob Banerjee, Muhammad Akram, Deepu Madduri, Sundar Jagannath, William Deraedt, Andrzej Jakubowiak, Tzu-Min Yeh, Adam D. Cohen, Yunsi Olyslager, Carolyn C. Jackson, Marlene Carrasco-Alfonso, Yi Lin, Parameswaran Hari
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S422-S423
Context Cilta-cel, a CAR-T cell therapy containing 2 BCMA-targeting single domain antibodies designed to confer high avidity binding, is being evaluated in the CARTITUDE-1 phase 1b/2 study. Objectives Provide updated results with a longer duration (m
Autor:
Julie R, Brahmer, Melissa L, Johnson, Manuel, Cobo, Santiago, Viteri, Juan Coves, Sarto, Ammar, Sukari, Mark M, Awad, Ravi, Salgia, Vali A, Papadimitrakopoulou, Arun, Rajan, Nibedita, Bandyopadhyay, Alicia J, Allred, Mark, Wade, Gary E, Mason, Enrique, Zudaire, Roland E, Knoblauch, Nicole, Stone, Matthew V, Lorenzi, Raffit, Hassan
Publikováno v:
JTO Clinical and Research Reports
Introduction JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted Listeria monocytogenes–based immunotherapy expressing human mesothelin. JNJ-757 was evaluated in patients with advanced NSCLC as monotherapy (phase 1) and in combination with
Autor:
Carolyn C. Jackson, Jesus G. Berdeja, William Deraedt, Andrzej Jakubowiak, Saad Z. Usmani, Sundar Jagannath, Jordan M. Schecter, Yunsi Olyslager, Mounzer Agha, Alicia J. Allred, Dong Geng, Thomas Martin, Arnob Banerjee, Deepu Madduri, Enrique Zudaire, Yi Lin, Changwei Zhou, Parameswaran Hari, Lida Bubuteishvili Pacaud, Tzu-Min Yeh, Adam D. Cohen
Publikováno v:
Blood. 138:3938-3938
Introduction: Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell (CAR-T) therapy with 2 B-cell maturation antigen (BCMA)-targeting single-domain antibodies, is being evaluated in patients (pts) with relapsed/refractory multiple